Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 3, 2026, 10:13 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 247 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Breast Magnetic Resonance Imaging (MRI) Clear all
Completed Not applicable Interventional

Extent of Breast Cancer and the Role of Pre-Operative Sonography and MRI

NCT02587663
View directory record Official record
Conditions
Ductal Breast Carcinoma In Situ, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer
Interventions
Contrast-enhanced Magnetic Resonance Imaging, Mammography, Therapeutic Conventional Surgery, Ultrasonography, Gadolinium
Procedure · Other
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older · Female only
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 16, 2019 · Synced Oct 3, 2026, 10:13 AM EDT
Recruiting Not applicable Interventional

Comparative Performance of Molecular Breast Imaging (MBI) to Magnetic Resonance Imaging (MRI) of the Breast in Identifying and Excluding Breast Carcinoma in Women at High Risk for Breast Cancer

NCT05042687
View directory record Official record
Conditions
Breast Cancer
Interventions
Tc99m sestamibi
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Oct 3, 2026, 10:13 AM EDT
Suspended No phase listed Observational

Safety, Ultrasound Conspicuity, and Migration of Twinkling Markers in Patients With Locally Advanced Breast Cancer

NCT05547347
View directory record Official record
Conditions
Anatomic Stage III Breast Cancer AJCC v8, Locally Advanced Breast Carcinoma, Resectable Breast Carcinoma
Interventions
Magnetic Resonance Imaging, Mammogram, Ultrasound, Ultrasound-Guided Biopsy, Twinkle marker
Procedure · Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Oct 3, 2026, 10:13 AM EDT
Completed No phase listed Observational

Monitoring Response to Neoadjuvant Chemotherapy by the Use of Breast Proton MR Spectroscopy

NCT00580086
View directory record Official record
Conditions
Breast Cancer
Interventions
MR spectroscopy
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 24, 2009 · Synced Oct 3, 2026, 10:13 AM EDT
Terminated Phase 1 Interventional

Evaluation of Magnetic Resonance Imaging (MRI) vs Molecular Breast Imaging (Tc-MBI) in Breast Cancer Patients

NCT02024074
View directory record Official record
Conditions
Breast Cancer
Interventions
Sestamibi (Tc-MBI) scan of the breast
Other
Lead sponsor
Emory University
Other
Eligibility
18 Years and older · Female only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 6, 2015 · Synced Oct 3, 2026, 10:13 AM EDT
Terminated Not applicable Interventional Results available

Role of Positron Emission Mammography (PEM) Flex Solo II Positron Emission Tomography (PET) Scanner in Evaluating Neoadjuvant Chemotherapy Response in Patients With Breast Cancer

NCT01012440
View directory record Official record
Conditions
Breast Cancer
Interventions
PEM Flex Solo II PET Scanner, MRI scan
Device
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 75 Years · Female only
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 27, 2015 · Synced Oct 3, 2026, 10:13 AM EDT
Active, not recruiting Phase 1 Interventional

Veliparib and Carboplatin in Treating Patients With HER2-Negative Metastatic Breast Cancer

NCT01251874
View directory record Official record
Conditions
Recurrent Breast Carcinoma, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7, Stage IV Breast Cancer AJCC v6 and v7, Triple-Negative Breast Carcinoma
Interventions
Biospecimen Collection, Carboplatin, Computed Tomography, Fluorothymidine F-18, Positron Emission Tomography, Veliparib
Procedure · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2026
U.S. locations
3
States / cities
The Bronx, New York • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 3, 2026, 10:13 AM EDT
Completed Not applicable Interventional Results available

Evaluation of Breast CT

NCT00584233
View directory record Official record
Conditions
Breast Cancer
Interventions
computed tomography, MRI
Device
Lead sponsor
University of California, Davis
Other
Eligibility
35 Years and older · Female only
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2020
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Dec 6, 2022 · Synced Oct 3, 2026, 10:13 AM EDT
Recruiting Phase 2 Interventional

A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negative Breast Cancer

NCT07078604
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma
Interventions
CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine, Chemotherapy, Computed Tomography, Sargramostim, Biospecimen Collection, Positron Emission Tomography (PET), Image Guided Biopsy
Biological · Drug · Procedure
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Oct 3, 2026, 10:13 AM EDT
Terminated No phase listed Observational

Impact of Breast Magnetic Resonance Imaging (MRI) on Mastectomy Rates

NCT01166581
View directory record Official record
Conditions
Early Stage Breast Cancer
Interventions
Not listed
Lead sponsor
Summa Health System
Other
Eligibility
18 Years to 85 Years · Female only
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Akron, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 4, 2015 · Synced Oct 3, 2026, 10:13 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Advanced Diffusion Tensor MRI for Breast Cancer

NCT04774471
View directory record Official record
Conditions
Breast Cancer, Breast Diseases
Interventions
Evaluation of BIT-Motion software
Diagnostic Test
Lead sponsor
Endeavor Health
Other
Eligibility
18 Years and older · Female only
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Evanston, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 3, 2025 · Synced Oct 3, 2026, 10:13 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Precision Supplemental Imaging in Women With Dense Breasts

NCT07277738
View directory record Official record
Conditions
Breast Cancer, Cancer of the Breast
Interventions
Prognosia Breast, Mammogram, MRI
Device
Lead sponsor
Washington University School of Medicine
Other
Eligibility
25 Years to 55 Years · Female only
Enrollment
78 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 3, 2026, 10:13 AM EDT
Active, not recruiting Phase 2 Interventional Accepts healthy volunteers

A Radiotracer ([18F]FluorThanatrace) by PET/CT for the Imaging of Breast Cancer

NCT05226663
View directory record Official record
Conditions
Breast Carcinoma
Interventions
Computed Tomography, Fluorine F 18 Fluorthanatrace, Positron Emission Tomography
Procedure · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
3
States / cities
St Louis, Missouri • Philadelphia, Pennsylvania • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Oct 3, 2026, 10:13 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Pertuzumab and Trastuzumab as Neoadjuvant Treatment in Patients With HER2-Positive Breast Cancer

NCT01937117
View directory record Official record
Conditions
Breast Cancer
Interventions
Positron emission tomography (PET), Trastuzumab, Pertuzumab
Procedure · Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
10
States / cities
Birmingham, Alabama • Washington D.C., District of Columbia • Indianapolis, Indiana + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 3, 2026, 10:13 AM EDT
Completed Not applicable Interventional Results available

PET/CT or PET/MRI in Measuring Tumors in Patients Undergoing Clinical Imaging or With Newly Diagnosed Breast Cancer

NCT01892540
View directory record Official record
Conditions
Breast Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
positron emission tomography/computed tomography, PET/MRI, Position Device
Diagnostic Test · Device
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 4, 2020 · Synced Oct 3, 2026, 10:13 AM EDT
Recruiting Phase 2 Interventional

Adaptive Therapy With Capecitabine for Treatment of Metastatic ER Positive, HER2 Negative Breast Cancer

NCT06525766
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Estrogen-receptor-positive Breast Cancer, Metastatic HER2-Negative Breast Carcinoma, Metastatic Breast Cancer
Interventions
Biospecimen Collection, Bone Scan, Capecitabine, Computed Tomography, Magnetic Resonance Imaging, Questionnaire Administration
Procedure · Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 3, 2026, 10:13 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer

NCT01116648
View directory record Official record
Conditions
Fallopian Tube Carcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian High Grade Serous Adenocarcinoma, Ovarian Serous Adenocarcinoma, Ovarian Serous Surface Papillary Adenocarcinoma, Primary Peritoneal Serous Adenocarcinoma, Triple-Negative Breast Carcinoma
Interventions
Biopsy Procedure, Biospecimen Collection, Cediranib Maleate, Computed Tomography, Echocardiography Test, Magnetic Resonance Imaging, Multigated Acquisition Scan, Olaparib
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2027
U.S. locations
14
States / cities
Los Angeles, California • Chicago, Illinois • Evanston, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Oct 3, 2026, 10:13 AM EDT
Not listed No phase listed Observational

Assessing Breast Density's Value in Imaging - A Comparative Effectiveness Study

NCT02980848
View directory record Official record
Conditions
Breast Cancer
Interventions
Screening digital mammography, Screening digital breast tomosynthesis, Screening breast magnetic resonance imaging, Diagnostic mammography, Pre-operative breast magnetic resonance imaging
Other
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 89 Years · Female only
Enrollment
1,341,172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
7
States / cities
Davis, California • San Francisco, California • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2021 · Synced Oct 3, 2026, 10:13 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Post-Treatment Surveillance in Breast Cancer: Bringing CER to the Alliance

NCT02171078
View directory record Official record
Conditions
Breast Neoplasms
Interventions
Not listed
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
Female only
Enrollment
34,359 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 27, 2022 · Synced Oct 3, 2026, 10:13 AM EDT
Terminated Phase 3 Interventional Results available

Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer

NCT03199885
View directory record Official record
Conditions
Metastatic Breast Adenocarcinoma, Metastatic HER2-Positive Breast Carcinoma, Recurrent Breast Adenocarcinoma, Recurrent HER2-Positive Breast Carcinoma, Stage III Breast Cancer AJCC v7, Stage IV Breast Cancer AJCC v6 and v7, Unresectable Breast Carcinoma, Unresectable HER2-Positive Breast Carcinoma
Interventions
Atezolizumab, Biopsy, Bone Scan, Computed Tomography, Docetaxel, Magnetic Resonance Imaging, Paclitaxel, Pertuzumab, Placebo Administration, Quality-of-Life Assessment, Trastuzumab
Drug · Procedure · Biological + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
662
States / cities
Birmingham, Alabama • Anchorage, Alaska • Gilbert, Arizona + 506 more
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Oct 3, 2026, 10:13 AM EDT
Completed Phase 2 Interventional Results available

Phase II Study of Fluorine-18 3'-Deoxy-3'-Fluorothymidine (F-18-FLT) in Invasive Breast Cancer

NCT00572728
View directory record Official record
Conditions
Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Interventions
CT, 18F-FLT, PET
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
27
States / cities
Scottsdale, Arizona • Little Rock, Arkansas • Los Angeles, California + 16 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2016 · Synced Oct 3, 2026, 10:13 AM EDT
Terminated No phase listed Observational

3-Dimensional Form and Soft Tissue Biomechanics of the Breast

NCT00502814
View directory record Official record
Conditions
Breast Cancer
Interventions
3-D Optical Surface Scan, Mechanical Testing, Cutaneous Ultrasound, Breast MRI and/or CT
Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 22, 2012 · Synced Oct 3, 2026, 10:13 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Estradiol in Treating Patients With ER Beta Positive, Triple Negative Locally Advanced or Metastatic Breast Cancer

NCT03941730
View directory record Official record
Conditions
Advanced Triple-Negative Breast Carcinoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma, Recurrent Breast Carcinoma
Interventions
Biopsy, Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography, Therapeutic Estradiol
Procedure · Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
9
States / cities
Birmingham, Alabama • San Francisco, California • Washington D.C., District of Columbia + 5 more
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Oct 3, 2026, 10:13 AM EDT
Terminated Not applicable Interventional Results available

Feasibility Study of Vessel Analysis for Noninvasive Diagnosis of Malignancy in Breast Tumors

NCT00630292
View directory record Official record
Conditions
Breast Cancer
Interventions
Magnetic Resonance Angiography (MRA) of the Breast
Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older · Female only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 18, 2010 · Synced Oct 3, 2026, 10:13 AM EDT